 | | Vol. 14.25 – 7 July, 2022 |
| |
|
|
| Scientists discovered for the first time that HMGN4 was highly expressed in human TNBC, based on the analysis of the TCGA database. They found that HMGN4 controlled the proliferation of human TNBC cells both in vitro and in vivo.
[Carcinogenesis] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In vitro experiments confirmed that Syringin inhibited the proliferation and migration of breast cancer cells and promoted apoptosis.
[Journal of Translational Medicine] |
|
|
|
| Cell counting kit-8 assays confirmed that the proliferation of the breast cancer (BC) cell lines were significantly increased following knockdown of MBP1 expression, while overexpression of MBP1 significantly inhibited the proliferation of the BC cell lines.
[Oncology Reports] |
|
|
|
| Researchers investigated the miRNA-mediated regulation of SOX9 expression in two breast cancer cell lines, thereby providing further insights into cellular mechanisms driving breast cancer progression.
[Molecular and Cellular Biochemistry] |
|
|
|
| In vitro results revealed upregulation of the expression of TUNEL and Bax in both MCF-7 and MDA-MB-231 cell lines regarding melatonin dose and time, but downregulation of Bcl-2 expression.
[Fundamental & Clinical Pharmacology] |
|
|
|
| Researchers reported that HCAR1 was highly expressed in breast cancer cells. Genetic deletion of HCAR1 in MCF7 cells led to reduced cell proliferation and migration.
[Molecular Medicine Reports] |
|
|
|
| Scientists found that the expression of hsa_circ_0012673 was upregulated in breast cancer tissues and cell lines.
[Molecular Biotechnology] |
|
|
|
|
| The authors present some of the latest advances concerning the role of LncRNAs in breast cancer.
[Cancer Gene Therapy] |
|
|
|
|
| CytomX Therapeutics, Inc. announced that the Phase II study of praluzatamab ravtansine in patients with hormone receptor-positive/HER2-non-amplified breast cancer met its primary efficacy endpoint of confirmed objective response rate of greater than 10% by central radiology review.
[CytomX Therapeutics, Inc.] |
|
|
|
|
| December 10 – 14, 2022
Maui, Hawai’i, United States |
|
|
|
|
|
| | Universit̩ catholique de Louvain РBrussels, Belgium |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
